Exelixis, Inc. Grows Revenue, Eyes Treating More Patients
Sales of Exelixis' (NASDAQ: EXEL) kidney cancer drug Cabometyx continued to grow at a torrid pace in the second quarter, allowing the company to post another profitable quarter.
Metric
Q2 2017
Source: Fool.com
Bristol-Myers Squibb Stock
€40.88
0.110%
Our community is currently high on Bristol-Myers Squibb with 11 Buy predictions and 3 Sell predictions.
With a target price of 67 € there is a hugely positive potential of 63.91% for Bristol-Myers Squibb compared to the current price of 40.88 €.